Evidence map›Paper›PMID 35838522›Full record

ArticleDrug delivery2022

Compression-coated pulsatile chronomodulated therapeutic system: QbD assisted optimization.

Hibah M Aldawsari, N Raghavendra Naveen, Nabil A Alhakamy, Prakash S Goudanavar, Gsn Koteswara Rao, Roja Rani Budha, Anroop B Nair, Shaimaa M Badr-Eldin

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. QbD driven targeted pulmonary delivery of dexamethasone-loaded chitosan microspheres: Biodistribution and pharmacokinetic study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Hibah M AldawsariDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
N Raghavendra NaveenDepartment of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, Karnataka, India.ORCID 0000-0002-8048-2438
Nabil A AlhakamyDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-3826-1519
Prakash S GoudanavarDepartment of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, Karnataka, India.ORCID 0000-0002-2511-8828
Gsn Koteswara RaoDepartment of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India.ORCID 0000-0003-1257-7133
Roja Rani BudhaInstitute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati, India.ORCID 0000-0002-9073-8927
Anroop B NairDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.ORCID 0000-0003-2850-8669
Shaimaa M Badr-EldinDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
King Abdulaziz University · SAGalgotias University · INKing Faisal University · SASri Padmavati Mahila Visvavidyalayam · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulsatile drug delivery systems have drawn attention in contemporary research for designing chronotherapeutic systems. The current work aims to design pulsatile ketorolac tromethamine tablets using compression coating for delayed delivery with a lag time suitable for the treatment of morning stiffness in arthritis. Rapidly disintegrating core tablets of ketorolac tromethamine were formulated using super-disintegrants, and the optimized formulation was compression using PEO WSR coagulant and Eudragit RLPO for delaying the release. The central composite design and response surface methodology were employed to optimize the formulation and process parameters namely PEO WSR Coagulant (X

Indexed as

Chemistry, PharmaceuticalKetorolac TromethamineDelayed-Action PreparationsDrug Delivery SystemsReproducibility of ResultsTabletsDelayed-Action PreparationsKetorolac TromethamineTabletschronobiologyCompression coatingEudragit RLPOketorolac tromethaminePEO WSR coagulantquality by design

Identifiers

PMID35838522
PMCPMC9477481
OpenAlexW4285585228

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.